Clinical Imaging
Volume 34, Issue 3 , Pages 191-195 , May 2010

Computed tomographic peritoneography prior to intraperitoneal chemotherapy in advanced müllerian cancer: a pilot study

Received 20 March 2009 ,Accepted 1 May 2009.

References 

  1. Weisberger AS, Levine B, Storaasli JP. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. J Am Med Assoc. 1955;159(18):1704–1707
  2. Dedrick RL, Myers CE, Bungay PM, DeVita VT. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62(1):1–11
  3. Markman M. Intraperitoneal drug delivery of antineoplastics. Drugs. 2001;61(8):1057–1065
  4. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335(26):1950–1955
  5. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19(4):1001–1007
  6. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34–43
  7. National Cancer Institute . Clinical announcement: intraperitoneal chemotherapy for ovarian cancer. January 4, 2006. http://wwwcancergov/newscenter/pressreleases/IPchemotherapyrelease
  8. Elit L, Oliver TK, Covens A, Kwon J, Fung MF, Hirte HW, et al. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses. Cancer. 2007;109(4):692–702
  9. Dunnick NR, Jones RB, Doppman JL, Speyer J, Myers CE. Intraperitoneal contrast infusion for assessment of intraperitoneal fluid dynamics. AJR Am J Roentgenol. 1979;133(2):221–223
  10. Twardowski ZJ, Tully RJ, Ersoy FF, Dedhia NM. Computerized tomography with and without intraperitoneal contrast for determination of intraabdominal fluid distribution and diagnosis of complications in peritoneal dialysis patients. ASAIO Trans. 1990;36(2):95–103
  11. Muggia FM, LePoidevin E, Jeffers S, Russell C, Boswell W, Morrow CP, et al. Intraperitoneal therapy for ovarian cancer: analysis of fluid distribution by computerized tomography. Ann Oncol. 1992;3(2):149–154
  12. Hughes PM, Zammit-Maempel I, Murphy D. Computed tomographic assessment of intraperitoneal fluid distribution prior to intraperitoneal chemotherapy for ovarian cancer. Br J Radiol. 1992;65(772):295–297
  13. Yoonessi M, Abdel-Dayem HM, Shalaby OF. The use of scintigraphic and contrast peritoneography in gynecologic malignancies. Diagn Gynecol Obstet. 1982;4(1):75–78
  14. Wahl RL, Gyves J, Gross BH, Cochran M, Juni JE, Arnstein NB, et al. SPECT of the peritoneal cavity: method for delineating intraperitoneal fluid distribution. AJR Am J Roentgenol. 1989;152(6):1205–1210
  15. de Forni M, Boneu A, Otal P, Martel P, Shubinski R, Bugat R, et al. Anatomic changes in the abdominal cavity during intraperitoneal chemotherapy: prospective study using scintigraphic peritoneography. Bull Cancer. 1993;80(4):345–350
  16. Sugimura K, Okizuka H, Kaji Y, Ishida T, Iwanari O, Kitao M. Prediction of effectiveness of intraperitoneal chemotherapy by intraperitoneal scintigraphy in patients with advanced ovarian carcinoma. Clin Nucl Med. 1994;19(7):600–603
  17. Piccart MJ, Floquet A, Scarfone G, Willemse PH, Emerich J, Vergote I, et al. Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int J Gynecol Cancer. 2003;13(Suppl 2):196–203
  18. Varia MA, Stehman FB, Bundy BN, Benda JA, Clarke-Pearson DL, Alvarez RD, et al. Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group. J Clin Oncol. 2003;21(15):2849–2855
  19. Young RC, Brady MF, Nieberg RK, Long HJ, Mayer AR, Lentz SS, et al. Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin—a gynecologic oncology group study. J Clin Oncol. 2003;21(23):4350–4355
  20. Frasci G, Contino A, Iaffaioli RV, Mastrantonio P, Conforti S, Persico G. Computerized tomography of the abdomen and pelvis with peritoneal administration of soluble contrast (IPC-CT) in detection of residual disease for patients with ovarian cancer. Gynecol Oncol. 1994;52(2):154–160
  21. Giunta S, Venturo I, Mottolese M, Salzano M, Diotallevi F, Squillaci S, et al. Noninvasive monitoring of ovarian cancer: improved results using CT with intraperitoneal contrast combined with immunocytology. Gynecol Oncol. 1994;53(1):103–108
  22. Makhija S, Leitao M, Sabbatini P, Bellin N, Almadrones L, Leon L, et al. Complications associated with intraperitoneal chemotherapy catheters. Gynecol Oncol. 2001;81(1):77–81
  23. Keshaviah P, Emerson PF, Vonesh EF, Brandes JC. Relationship between body size, fill volume, and mass transfer area coefficient in peritoneal dialysis. J Am Soc Nephrol. 1994;4(10):1820–1826

PII: S0899-7071(09)00116-8

doi: 10.1016/j.clinimag.2009.05.009

Clinical Imaging
Volume 34, Issue 3 , Pages 191-195 , May 2010

Article Tools

* Image Usage & Resolution